Merck KGaA partners with Valo Health in a $3bn deal for drug discovery, focusing on Parkinson’s disease. Valo’s AI platform analyzes patient data to identify therapeutic targets, followed by developing molecules. This collaboration aims to accelerate drug discovery for high unmet medical needs. Other pharma giants like Novo and Pfizer are also leveraging Valo’s tech in their pipelines.

Valo’s CEO Brian Alexander is optimistic about expanding Merck’s Parkinson’s treatment pipeline using their platform. By leveraging real-world data and AI, Valo aims to unravel disease complexities and validate therapeutic targets efficiently. The partnership with Merck signifies a strategic move towards advancing innovative treatments for neurological disorders.

Read more at Yahoo Finance: Merck KGaA eyes new Parkinson’s disease assets with $3bn Valo partnership